


COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY 4377

The revision of the labeling of chloramphenicol was approved by a special committee of experts in hematology, infectious diseases and other medical fields convened by the Food and Drug Administration on February 26, 1968. A copy of the revised labeling is enclosed for your attention.

To assist us in further evaluation of this problem, the Food and Drug Administration requests that you report to us any adverse reactions associated with the use of chloramphenicol. A facsimile of our Drug Experience Report (FD 1639) is reproduced on the reverse side for your information. If you wish a supply, please write to the Food and Drug Administration, Bureau of Medicine, Washington, D.C. 20204.

Sincerely yours,


James L. Goddard, M.D.
Commissioner of Food and Drugs

Enclosure:
Revised Labeling